OptimizeRx Corp.

How big is OptimizeRx Corp.?

As of Jun 18, OptimizeRx Corp. has a market capitalization of 247.83 million and reported net sales of 94.37 million with a net profit of -15.41 million over the latest four quarters.

Market Cap: As of Jun 18, OptimizeRx Corp. has a market capitalization of 247.83 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, OptimizeRx Corp. reported net sales of 94.37 million and a net profit of -15.41 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 117.00 million and total assets of 171.17 million.

What does OptimizeRx Corp. do?

OptimizeRx Corporation is a digital health company that enhances communication among healthcare stakeholders at the point-of-care. As of March 2025, it reported net sales of $22 million and a market cap of $247.83 million, but is currently operating at a loss.

Overview: <BR>OptimizeRx Corporation is a digital health company that facilitates communication at point-of-care among stakeholders in healthcare, operating within the Software Products industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 22 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 247.83 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.14 <BR>Return on Equity: -6.81% <BR>Price to Book: 2.13<BR><BR>Contact Details: <BR>Address: 400 Water St Ste 200, ROCHESTER MI: 48307-2090 <BR>Tel: ['1 248 6516558', '1 949 4327557'] <BR>Fax: 1 248 4535529 <BR>Website: https://www.optimizerx.com/

Should I buy, sell or hold OptimizeRx Corp.?

Who are in the management team of OptimizeRx Corp.?

As of March 2022, the management team of OptimizeRx Corp. includes Chairman Gus Halas, CEO William Febbo, and Directors Gregory Wasson, James Lang, Patrick Spangler, and Lynn Vos. They oversee the company's strategic direction and operations.

As of March 2022, the management team of OptimizeRx Corp. includes the following individuals:<BR><BR>- Mr. Gus Halas, Chairman of the Board<BR>- Mr. William Febbo, Chief Executive Officer and Director<BR>- Mr. Gregory Wasson, Director<BR>- Mr. James Lang, Independent Director<BR>- Mr. Patrick Spangler, Independent Director<BR>- Ms. Lynn Vos, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is OptimizeRx Corp. overvalued or undervalued?

As of May 4, 2022, OptimizeRx Corp. is considered overvalued with a risky valuation grade due to negative valuation ratios, including an EV to EBIT of -86.78 and a high EV to EBITDA of 271.52, despite a strong year-to-date stock performance of 289.30%.

As of 4 May 2022, OptimizeRx Corp. moved from a fair to a risky valuation grade. The company appears to be overvalued, given its significant negative valuation ratios, including an EV to EBIT of -86.78 and a P/E ratio that is not applicable due to losses. Additionally, its Price to Book Value stands at 2.33, indicating a premium over its book value, which is concerning in the context of its financial performance.<BR><BR>In comparison to peers, OptimizeRx Corp. has a notably high EV to EBITDA ratio of 271.52, while Blacksky Technology, Inc. has a much lower EV to EBITDA of -67.11, and ReposiTrak, Inc. shows a fair valuation with a P/E of 47.10. The company's recent stock performance has been impressive, with a year-to-date return of 289.30%, significantly outperforming the S&P 500's 12.22% return, but this does not mitigate the underlying valuation concerns.

Is OptimizeRx Corp. technically bullish or bearish?

As of September 12, 2025, OptimizeRx Corp. has a mildly bullish technical trend, supported by bullish MACD and Bollinger Bands, despite mixed signals from KST and Dow Theory, and it has significantly outperformed the S&P 500 year-to-date with a return of 289.30%.

As of 12 September 2025, the technical trend for OptimizeRx Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. However, the KST shows a mildly bearish signal on the weekly timeframe, and Dow Theory is mildly bearish on the weekly but mildly bullish on the monthly. The daily moving averages are bullish, suggesting short-term strength.<BR><BR>In terms of performance, OptimizeRx has significantly outperformed the S&P 500 year-to-date with a return of 289.30% compared to the S&P's 12.22%, and over the past year, it has returned 146.35% versus the S&P's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and Bollinger Bands, despite some mixed indicators in the KST and Dow Theory.